Markets:

Overview

News

Currencies

International

Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

31.06 -0.20 (-0.64%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023

February 03, 2023

Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET

From Celldex Therapeutics, Inc.

Via GlobeNewswire

These '20 Stocks To Watch' Moved On Last Fed Rate Hike: How Will They React Today? ↗

February 01, 2023

The Federal Reserve's interest rate hike announcements have the potential to cause significant volatility in the stock market.

Via Benzinga

Celldex Therapeutics Earnings Perspective: Return On Capital Employed ↗

December 19, 2022

Via Benzinga

Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data ↗

July 05, 2022

Via Benzinga

Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study ↗

July 01, 2022

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

December 14, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Topics Death

BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

December 14, 2022

Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing...

Via TheNewswire.com

Topics Death

BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients ↗

December 13, 2022

Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX<

Via Benzinga

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022

December 06, 2022

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

December 02, 2022

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex to Participate in Upcoming November Investor Conferences

November 10, 2022

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 09, 2022

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics Earnings Perspective: Return On Capital Employed ↗

August 31, 2022

Celldex Therapeutics (NASDAQ:CLDX) brought in sales totaling $163 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 56.2%, resulting in a loss of $36.00...

Via Benzinga

Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday ↗

July 05, 2022

Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday.

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know ↗

July 01, 2022

HC Wainwright & Co. has decided to maintain its Buy rating of Celldex Therapeutics (NASDAQ:CLDX) and raise its price target from $60.00 to $73.00. Shares of Celldex Therapeutics are trading down 14.91%...

Via Benzinga

Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session ↗

July 01, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.

Via Benzinga

Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug ↗

July 01, 2022

The study was in 26 patients with chronic hives that don't respond to antihistamines.

Via Investor's Business Daily

Why U.S. Stocks Are Trading Higher, Manufacturing Report And More ↗

July 01, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

June 02, 2022

During the Thursday's session, 100 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

On Wednesday, 73 stocks hit new 52-week lows.

Via Benzinga

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years ↗

May 11, 2022

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

Via InvestorPlace

77 Biggest Movers From Yesterday ↗

June 01, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate...

Via Benzinga

Celldex Therapeutics: Q4 Earnings Insights ↗

February 28, 2022

Celldex Therapeutics (NASDAQ:CLDX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

The Secret To Successful Investing In Biotech ↗

October 19, 2021

Have you ever had a stock jump 30%, 50% or 100% in one day?

Via Talk Markets

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 15, 2021

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares moved upwards by 29.96% to $7.72 during Friday's pre-market session. The company's market cap stands at $20.8...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

All News about Celldex Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today